search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
66 SKIN CARE


Photography – Canfield Visia images The results of the blinded photographic comparison of the before and after treatment images are shown in Table 5. A score was allocated from -3 (A markedly worse than B), through 0 (no difference) to +3 (A markedly better than B), for the blinded, randomised paired images. After decoding to active or placebo treatment, the mean and median scores for each volunteer are shown in Table 5. The data show a highly significant


difference in the mean and median change in skin appearance for the active and placebo treated sides of the face. For the active treated side of the face, the mean score was +0.35, with a median of +1, whereas for the placebo treated side, the mean was -0.48, with a median change of - 1. Across the 32 volunteers, the sum of the scores was +11 for the active group and - 15 for the placebo group. An unpaired t- test, comparing the mean scores for the active and placebo group, showed a highly significant difference between the active and placebo groups (p=0.004), demonstrating a perceivable improvement in skin appearance for the active group and a worsening of skin appearance for the placebo group. These results show that the active treated skin improved significantly over 10 weeks, whereas the placebo treated skin worsened. This is consistent with the instrumental data and further demonstrates that even with UV exposure during the summer months of this study, the active treatment improved skin appearance, whereas the placebo treatment failed to protect skin from worsening in appearance. Examples of left and right comparative


images of active and placebo treated sides of the face of the same volunteers (baseline versus week 10) are shown in Figure 3a: Note reduced hyperpigmentation and lighter skin tone for active treatment. Note reduced crows’ feet, nasiolabal fold and forehead wrinkles for active treatment (Fig 3b). Note reduced pigmentation and greater evenness of skin tone for active treatment (Fig 3c).


Table 6: Chromameter data - lightness A


T0 Mean


Median SD


Min max


B Mean


Median SD


Min max


61.42356 61.807


3.417972 52.99


67.608 T0


61.2035 61.849


3.640044 50.252 68.186


PERSONAL CARE ASIA PACIFIC n Product A n Product B 42


37


32


27


22 baseline week10


Figure 5: Change in moisturisation between baseline and week 10.


Table 5: Blinded photographic comparison Analysis


Active


Mean Change Median Change Sum of Change T-test p value


0.354839 1


11 0.004443


Chromameter data The individual results of the chromameter analysis parameter L* (lightness) are summarised in Table 6. The side of the face treated with Product


A became lighter by 3% between baseline and week 8, decreasing to less than 1% at week 10, whereas the side of the face treated with Product B became darker by 2% between baseline and week 8 and was maintained at week 10. Additionally, the difference in overall skin lightness between the side of the face treated with Product A and Product B at week 10 was 2%. There were statistically significant


changes (p<0.05) for the mean L* (lightness parameter) between baseline and week 4 and week 8 for Product A, indicating a statistically significant increase in overall skin lightness. For Product B, there were


T10


61.16558 61.362


3.059904 52.402 68.548 T10


60.23794 60.71


3.599518 48.276 68.25


Table 7: Green/Red A


Mean


Median SD


Min max


B Mean


Median SD


Min max


-15


Placebo -0.48387 -1


statistically significant (p<0.05) changes in skin lightness at all time points, indicating that skin became statistically significantly darker throughout the study. In addition, the difference in mean L* parameter between Product A treated skin and Product B treated skin was highly statistically significantly different at week 10 (P<0.001) indicating that the side of the face treated with Product A was statistically significantly lighter in overall brightness than the half of the face treated with Product B. The side of the face treated with Product


A became less red by 1% between baseline and week 10, whereas the side of the face treated with Product B became redder by 3% between baseline and week 10. Additionally, the difference in overall skin redness between the side of the face treated with Product A and Product B at week 10 was 4%. There were statistically significant


changes (p<0.05) for the mean a* (red parameter) (Table 7) between baseline and week 4 and week 8 for Product A, indicating a statistically significant decrease in overall skin redness. In addition, the


T0


12.51294 12.304


2.176352 8.554


18.866 T0


12.45133 12.338


2.495014 7.848


17.578 T10


12.33413 11.842


2.287328 8.762


19.102 T10


12.82419 12.27


2.787912 8.32


22.69 November 2020


Corneometer value


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96